President Trump’s statements about prescription drug prices don’t add up. Despite advice from many experts, including Health Secretary Robert F. Kennedy Jr., the administration insists Trump’s claims are accurate.
Over the past year, Trump has boasted about reducing drug prices by absurd percentages—like “500%” and “1,500%.” However, as several fact-checkers have pointed out, these figures aren’t mathematically sound. A decrease of 100% would mean medications are free. Therefore, saying prices dropped by more than 100% implies people would get paid to take their medicine, which is not the case.
This scenario reflects a trend where officials seem eager to support Trump’s exaggerated statements, even when they don’t hold up under scrutiny. Recent attempts to defend these claims included a Senate hearing where Sen. Elizabeth Warren confronted Kennedy about Trump’s “600%” reductions.
Kennedy responded with flawed math that suggested a drop from $600 to $10 was indeed a “600% reduction.” In reality, it’s about a 98.3% drop—an important distinction that underscores the need for accurate calculations.
Social media users quickly mocked Kennedy’s comments, reflecting a growing trend of public skepticism around Trump’s numerical claims. This disbelief resonates across platforms where users scrutinize politicians’ statements.
Another high-profile Trump official, Dr. Mehmet Oz, also attempted to justify misleading percentages. At an event, he argued that a drug price drop from $242 to $10 was so substantial that calculating the exact percentage was nearly impossible. Yet, it simply equates to a 95.9% reduction—far from unreachable.
In a recent NBC interview, Oz again tried to rationalize Trump’s math by saying a price drop from $100 to $50 is a “100% cut.” This, of course, is incorrect; it’s a straightforward 50% reduction. When challenged on Trump’s claim of “1,500%” cuts, Oz continued to leverage fanciful math, responding with similarly erroneous calculations.
Surveys reveal that nearly 80% of Americans are concerned about prescription drug prices in the U.S., where many pay far more than their counterparts in other developed countries. For instance, a drug priced at $521 in the U.S. may cost just $45 in Australia, highlighting the issue of inflated U.S. prices rather than exaggerated claims of reductions.
While the administration tries to address the problem of high drug costs with oversimplified solutions, true change requires acknowledging the complexity of pricing mechanisms and focusing on realistic, achievable reforms. In the ongoing discussion, accurate information and responsible communication are crucial. As the public becomes increasingly aware of these discrepancies, officials must reckon with the demand for honesty and clarity in their messaging.
For more detailed insights on prescription drug pricing, consider looking at this report by the Kaiser Family Foundation.
